Key result
Polymeric doxorubicin formulation increases survival by ~100% vs free drug while reducing cardiotoxicity.
Why the study?
The cardiotoxic effects of novel synthetic 4-thiazolidone derivatives and their complexes with a polyethylenglycol-containing polymeric carrier compared to doxorubicin were not well characterized in rat blood serum.
Answers are grounded in this paper and cite their sources.
May inform less cardiotoxic doxorubicin regimens; leaves open translation to clinical trials.
The aim of this study was to measure the activity of enzymes which reflect cardiotoxic action in rats of novel synthetic 4-thiazolidone derivatives--3882, 3288 and 3833 that demonstrated antineoplastic effect in vitro towards 60 lines of human tumor cells tested in the framework of the program of screening new anticancer drugs at the National Cancer Institute (USA). Such action of these compounds was compared with the effect of well known anticancer agent doxorubicin and after conjugation of all above mentioned substances with new polyethylenglycol-containing polymeric comb-like carrier that was synthesized by the authors. Among the biochemical indicators of cardiotoxic action of anticancer agents, activity of the following enzymes in rat blood serum showed to be the most informative: creatine kinase, lactate dehydrogenase, aspartate aminotransferase, and alanine aminotransterase. Tenfold injection of doxorubicin in a dose of 5.5 mg/kg of weight caused rats' death, while 3882, 3288 and 3833 preparations had not such action. Application of the doxorubicin in combination with polymeric carrier prolonged the survival time to 20 days. Thus, the injection of anticancer agents in a complex with polymeric carrier provides a significant decrease in their cardiotoxicity that was confirmed by the corresponding changes in the activity of marker enzymes: creatine kinase, lactate dehydrogenase, aspartate aminotransferase and alanine aminotransferase in blood serum of treated rats.
No takes yet. Share an insight, caveat, or question.
Lesya I. Коbylinska (2014) studied Cardiotoxicity of antitumor agents (n=220). 4-thiazolidinone derivatives (3882, 3288, 3833) and doxorubicin in complexes with PEG-containing polymeric carrier vs. Free doxorubicin, free 4-thiazolidinone derivatives, and intact control was evaluated on Survival time and activity of cardiotoxicity marker enzymes (creatine kinase, lactate dehydrogenase, AST, ALT) in blood serum (p=<0.05). Administration of doxorubicin in combination with a polymeric carrier prolonged rat survival time to 20 days compared to 10 days for free doxorubicin, and complexes of 4-thiazolidinone derivatives significantly decreased cardiotoxicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: